Loading...
•
Jun 30, 2020
Molina Q2 2020 Earnings Report
Molina Healthcare's financial performance improved with increased premium revenue and net income, driven by effective cost management and the impacts of the COVID-19 pandemic.
Key Takeaways
Molina Healthcare reported a strong second quarter with increased net income and premium revenue. The company's performance was positively impacted by reduced demand for medical services due to the COVID-19 pandemic, which was partially offset by COVID-related premium rate refunds and direct medical costs. The company introduced full year 2021 premium revenue guidance of approximately $21.5 billion, representing 20% growth over 2020.
Premium revenue increased by 8.0% to $4.4 billion compared to the second quarter of 2019.
Medical care ratio (MCR) improved to 82.3% compared to 85.6% in the second quarter of 2019.
Net income rose to $276 million, compared to $196 million for the second quarter of 2019.
The company estimates that COVID-19 increased second quarter after-tax income by approximately $65 million to $100 million.
Molina
Molina
Forward Guidance
The Company has increased its full year 2020 total revenue outlook to approximately $18.8 billion, from its previous estimate of $18.3 billion. The Company introduced full year 2021 premium revenue guidance of approximately $21.5 billion, or 20% growth over 2020.
Positive Outlook
- Full year earnings guidance range remains at $11.20 to $11.70 per diluted share.
- Full year 2020 total revenue outlook increased to approximately $18.8 billion.
- Full year 2021 premium revenue guidance of approximately $21.5 billion, or 20% growth over 2020.
- Kentucky Medicaid managed care RFP was awarded to Molina.
- Acquisition of YourCare assets was completed.
Challenges Ahead
- Environmental uncertainty is expected to exist through the end of the year.
- COVID-related premium rate refunds.
- Impact of lower pricing in the Marketplace program.
- Direct COVID-19 medical costs.
- Unspecified risks and uncertainties that could affect future developments.